公开(公告)号：US20230321253A1

公开(公告)日：2023-10-12

申请号：US18119592

申请日：2023-03-09

Applicant: RISEN (SUZHOU) PHARMA TECH CO., LTD.

Inventor： Jiasheng LV ,  Xiangyang LI ,  Xiang JI ,  Yuhui CHEN ,  Yongyue CHEN ,  Chuanhao HUANG ,  Xingwu ZHU ,  Xiaolin HE ,  Jian GE ,  Tianlun ZHOU ,  Xianqi KONG ,  Dawei CHEN ,  Xiangsheng YE

IPC: A61K47/54 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K47/545 ,  A61K45/06 ,  A61P35/00

Abstract: The disclosure relates to bifunctional KRAS-G12D-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to KRAS-G12D protein, T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects W and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of the KRAS-G12D protein in a cell and are thus useful for treating, inhibiting, and preventing KRAS-G12D-associated diseases, disorders and conditions, including cancers.

公开(公告)号：US20240024346A1

公开(公告)日：2024-01-25

申请号：US18021709

申请日：2021-11-25

Applicant: RISEN (SUZHOU) PHARMA TECH CO., LTD. ,  Jiasheng LU ,  Gang CHEN ,  Qiguo ZHANG ,  Xianqi KONG ,  Dawei CHEN ,  Chuanhao HUANG ,  Xingwu ZHU ,  Yuhua ZHANG

Inventor： Jiasheng LU ,  Gang CHEN ,  Qiguo ZHANG ,  Xianqi KONG ,  Dawei CHEN ,  Chuanhao HUANG ,  Xingwu ZHU ,  Yuhua ZHANG

IPC: A61K31/7076 ,  C07H19/20 ,  A61K45/06

CPC classification number: A61K31/7076 ,  A61K45/06 ,  C07H19/20

Abstract: CD73 (also known as ecto-5′-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I′ and pharmaceutically acceptable esters or salts thereof.

公开(公告)号：US20240116952A1

公开(公告)日：2024-04-11

申请号：US18463439

申请日：2023-09-08

Applicant: RISEN (SUZHOU) PHARMA TECH CO., LTD.

Inventor： Jiasheng LU ,  Xiang JI ,  Xianchao DU ,  Yanpeng WU ,  Xiaolin HE ,  Guangwei REN ,  Lina CHU ,  Chuanhao HUANG ,  Xingwu ZHU ,  Yuhua ZHANG ,  Jian GE ,  Tianlun ZHOU ,  Xiangsheng YE ,  Xianqi KONG ,  Dawei CHEN

IPC: C07D519/00 ,  A61K45/06 ,  A61P35/00 ,  C07F9/6561

CPC classification number: C07D519/00 ,  A61K45/06 ,  A61P35/00 ,  C07F9/6561

Abstract: The disclosure relates to KRASG12D inhibitor compounds having the structure of Formula (A) or Formula (B), pharmaceutical compositions thereof, and methods of use thereof for inhibiting, treating, and/or preventing KRASG12D mutation-associated diseases, disorders and conditions.

公开(公告)号：US20240059712A1

公开(公告)日：2024-02-22

申请号：US18466473

申请日：2023-09-13

Applicant: RISEN (SUZHOU) PHARMA TECH CO., LTD.

Inventor： Jiasheng LV ,  Xiang JI ,  Gang WU ,  Bin ZONG ,  Qiguo ZHANG ,  Yanpeng WU ,  Xiangyang LI ,  Yuhui CHEN ,  Yongyue CHEN ,  Chuanhao HUANG ,  Xingwu ZHU ,  Xiaolin HE ,  Yao LIU ,  Yuhua ZHANG ,  Jian GE ,  Tianlun ZHOU ,  Xiangsheng YE ,  Xianqi KONG ,  Dawei CHEN

IPC: C07D519/00

CPC classification number: C07D519/00

Abstract: The disclosure relates to bifunctional KRAS-G12D-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to KRAS-G12D protein, T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects W and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of the KRAS-G12D protein in a cell and are thus useful for treating, inhibiting, and preventing KRAS-G12D-associated diseases, disorders and conditions, including cancers.

公开(公告)号：US20230295213A1

公开(公告)日：2023-09-21

申请号：US17993937

申请日：2022-11-24

Applicant: RISEN (SUZHOU) PHARMA TECH CO., LTD.

Inventor： Jiasheng LU ,  Gang CHEN ,  Qiguo ZHANG ,  Xianqi KONG ,  Dawei CHEN ,  Chuanhao HUANG ,  Xingwu ZHU ,  Yuhua ZHANG

IPC: C07H19/20 ,  C07H19/16 ,  C07F9/6561

CPC classification number: C07H19/20 ,  C07H19/16 ,  C07F9/65616

Abstract: CD73 (also known as ecto-5′-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I′ and pharmaceutically acceptable esters or salts thereof.